Corrigendum to “A consensus introduction to serum replacements and serum-free media for cellular therapies” [Cytotherapy 19 (2017) 155–169]

OHAD KARNIELI1, ORYAN MAKLER FRIEDNER2, JULIE G. ALLICKSON1, NAN ZHANG3, SUNGHOON JUNG5, DAVID FIORENTINI6, EYTAN ABRAHAM5, SHANNON S. EAKER7, TAN KAH YONG8, ALLAN CHAN9, SARAH GRIFFITHS9, AMY K. WEHN10, STEVE OH8 & OHAD KARNIELI1

1Karnieli Ltd and ATVIO Biotech, Tivon, Israel, 2Pluristem Therapeutics, Matam Park, Haifa, Israel, 3Regenerative Medicine Clinical Center, Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA, 4Hematology Branch, National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, Maryland, USA, 5Cell Therapy Research & Technology Lonza Walkersville, Walkersville, Maryland, USA, 6Biological Industries Ltd., Beit Haemek, Israel, 7GE Healthcare Cell Therapy Division, Marlborough, Massachusetts, USA, 8Bioprocessing Technology Institute, Singapore, 9Stimlabs, Roswell, Georgia, USA, and 10Irvine Scientific, Santa Ana, California, USA

The authors apologize for reproducing several sentences from “Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?”, by Thierry Burnouf, Dirk Strunk, Mickey B.C. Koh, and Katharina Schallmoser, Biomaterials, 76, 371–387, and for failing to cite the article. Additionally, we apologize for reproducing three sentences from “Human AB serum as an alternative to fetal bovine serum for endothelial and cancer cell culture”, by D. Canovas and N. Bird, ALTEX 2012;29(4):426-8, and for not citing this work.

Our paper was a joint effort of an expert committee with multiple authors of which each one wrote several parts in several sections trying to reach a consensus among the experts. Therefore, within the multiple revisions the relevant citations were mishandled.

Once again, we apologize to the above authors for these failures and to the readers, and thank you for your understanding.